FY25 consensus $29.97. In a regulatory filing, the company stated, “Officers of Elevance Health (ELV) expect to speak with investors over the next week. During these meetings, company officers expect to reaffirm the company’s shareholders’ earnings guidance for full year 2025 to be approximately $24.70 per diluted share, including approximately $5.30 per diluted share of net unfavorable items. Excluding these items, the company continues to expect adjusted shareholders’ earnings to be approximately $30.00 per diluted share. This does not include any other adjustment items beyond those reported in the company’s third quarter 2025 earnings. During these meetings, company officers are also expected to reaffirm full year 2025 benefit expense ratio guidance of approximately 90.0%.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Trump Trade: Trump says ‘enrichment’ of health insurers ‘must stop’
- Video: Health insurers weighed on by shutdown news, Trump post
- Trump says ‘enrichment’ of health insurers ‘must stop’
- Elevance Health price target lowered to $400 from $420 at Mizuho
- Enrollees of ACA plans learn of hefty premium increases, WSJ reports
